If You Invested in Matricelf Ltd (MTRLF)
See the MTRLF overviewWhat $1,000 or $10,000 in MTRLF Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since Feb 8, 2022 |
|---|---|---|---|---|
| $1,000 | $1,000 +0% | — | — | $590 -41% |
| $10,000 | $10,000 +0% | — | — | $5,901 -41% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2024-09-04. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for MTRLF$1,000 Investment Over Time
MTRLF vs S&P 500Year-by-Year Returns
MTRLF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2022Feb 8, 2022 to Dec 30, 2022 | $3.22 | $1.90 | -41.0% | -41.0% |
| 2023 | $1.90 | $1.90 | +0.0% | -41.0% |
| 2024Dec 29, 2023 to Sep 4, 2024 | $1.90 | $1.90 | +0.0% | -41.0% |
About Matricelf Ltd
Healthcare · OTC
Matricelf Ltd. (MTRLF) develops personalized regenerative medicine technologies for engineered neural tissue implants intended for spinal cord injury. The company is a biotechnology issuer whose public announcements identify its Tel Aviv Stock Exchange ticker as MTLF. Its operating focus is tissue engineering: using patient-specific biological material, stem-cell biology, and a proprietary human extracellular-matrix hydrogel platform to create three-dimensional neural tissue for potential implantation in damaged spinal cord tissue.
The company's lead application is a personalized spinal cord implant designed as an autologous therapy. Autologous approaches use a patient's own biological material, which Matricelf describes as a way to reduce the risk of implant rejection. The platform is also described as a broader method for personal three-dimensional printing of tissues and organs, although the company's current public development emphasis is on neural tissue for spinal cord injury.
Technology platform
Matricelf's technology combines neural tissue engineering with a hydrogel platform based on human extracellular matrix. Company announcements describe engineered neural tissues evaluated through cellular, genetic, protein-level, and functional measures, including neural marker expression and electrical activity. The company has reported safety characterization work using advanced RNA sequencing methods to examine the cellular composition of implant batches as part of its preclinical development program.
The technology originated from research associated with Tel Aviv University and was licensed to Matricelf under an exclusive global licensing agreement signed in 2019. Company materials also describe work connected to the Sagol Center for Regenerative Biotechnology at Tel Aviv University, including preclinical research involving engineered spinal cord tissues in chronic spinal cord injury models.
Development and manufacturing focus
Matricelf operates as a development-stage regenerative medicine company. Its recurring activities include preclinical safety and efficacy work, manufacturing process development, clinical-grade production planning, and collaboration with external research and technology organizations. The company has described a strategic collaboration with the CiRA Foundation in Japan to evaluate induced pluripotent stem cells in combination with Matricelf's proprietary neural tissue engineering platform. The stated objective of that work is to assess compatibility with automated, large-scale manufacturing approaches for engineered neural tissues.
Matricelf has also reported manufacturing-related research involving stem cells generated through artificial-intelligence-based technology in collaboration with Cellino Biotech. These activities fit the company's broader focus on translating personalized regenerative implants from laboratory-scale engineering into processes that could support regulated clinical development.
Corporate profile
Matricelf is based in Israel, and company announcements cite facilities in Ness Ziona. Its public communications center on regenerative medicine, spinal cord injury, personalized neural tissue implants, collaborations in stem-cell manufacturing, preclinical testing, and preparation for human clinical development. The company's profile is defined by its autologous tissue-engineering platform rather than by marketed pharmaceutical products or a diversified commercial portfolio.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Matricelf Ltd investment returns
How much was $1,000 invested in Matricelf Ltd worth at its last close?
If you invested $1,000 in Matricelf Ltd (MTRLF) 1 year before its last close, on 2023-09-05, your investment was worth $1,000 on 2024-09-04, a +0.0% price return without dividends, growing at a compounded rate of 0.0% per year (CAGR).
Has Matricelf Ltd outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare MTRLF performance over available time periods.
What is Matricelf Ltd's average annual return?
The compound annual growth rate (CAGR) of MTRLF’s share price over the 1 year to Sep 4, 2024 is 0.0%, without dividends. Individual years vary a great deal, and MTRLF’s best recent full year was 2023 (+0.0%) while the worst was 2023 (+0.0%).
For informational and educational purposes only, not investment advice.
